Maveropepimut-s is under clinical development by IMV and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase II drugs for Epithelial Ovarian Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Maveropepimut-s’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Maveropepimut-s (DPX-Survivac) is under development for the treatment of glioblastoma, ovarian cancer, fallopian tube cancer, bladder cancer, liver cancer (hepatocellular carcinoma), non-small cell lung (NSCLC) cancer as well as tumors shown to be positive for the microsatellite instability-high (MSI-H) biomarker, diffuse large B-cell lymphoma, peritoneal cancer and (HR+/HER2-) breast cancer. It is administered subcutaneously. It comprises survivin-based antigens formulated in the DepoVax delivery platform and DPX platform. It was also under development for the treatment of prostate cancer.
IMV, formerly Immunovaccine Inc, is a biopharmaceutical company that develops immunotherapies and vaccines to treat cancer and infectious diseases. The company is investigating its pipeline candidates DPX-Survivac against ovarian, bladder, liver, non-small cell lung cancer and diffuse large B cell lymphoma (DLBCL); DPX-RSV for Respiratory Syncytial Virus (RSV); and DPX-Covid-19 for the treatment of coronavirus. It is also advancing DPX-SurMAGE against bladder cancer and DPX-BRAF to treat melanoma. IMV harnesses its proprietary DPX platform technology to deliver drugs. The company partners with pharmaceutical companies, academic research institutions and government agencies to research and develop therapies for cancer. IMV is headquartered in Dartmouth, Nova Scotia, Canada.
For a complete picture of Maveropepimut-s’s drug-specific PTSR and LoA scores, buy the report here.